title: Prognostic factors for gemcitabine-refractory patients with advanced pancreatic cancer: a retrospective analysis of a multicentre study (Anatolian Society of Medical Oncology).
abstract: OBJECTIVE
  Systemic chemotherapy for patients with pancreatic cancer has limited impact on overall survival (OS). Patients eligible for chemotherapy should be selected carefully. The aim of the study was to search for prognostic factors for survival in patients with gemcitabine (Gem)-refractory or with gemcitabine and cisplatin (GemCis)-refractory advanced pancreatic cancer.
  
  
  METHODS
  We retrospectively evaluated patients with Gem- or GemCis-refractory advanced pancreatic cancer. Sixteen potential prognostic variables were chosen for analysis in this study. Univariate and multivariate analyses were conducted to identify prognostic factors associated with survival. Univariate and multivariate statistical methods were used to determine prognostic factors.
  
  
  RESULTS
  Multivariate analysis included the four prognostic significance factors in univariate analysis. Multivariate analysis showed that liver metastasis and second-line chemotherapy were considered independent prognostic factors for survival.
  
  
  CONCLUSIONS
  Liver metastasis and second-line chemotherapy were identified as important prognostic factors in advanced pancreatic cancer patients refractory to treatment with Gem or GemCis. This prognostic factors may also facilitate pretreatment prediction of survival and can be used for selecting patients for treatment.
authors.affiliation: Department of Medical Oncology, School of Medicine, Dicle University, Diyarbakır, Turkey.
authors.forename: Ali
authors.initials: A
authors.lastname: İnal
authors.affiliation: Department of Medical Oncology, Ankara Numune Education and Research Hospital, Ankara, Turkey.
authors.forename: F Tuba
authors.initials: FT
authors.lastname: Kos
authors.affiliation: Department of Medical Oncology, Gazi University, Ankara, Turkey.
authors.forename: Efnan
authors.initials: E
authors.lastname: Algın
authors.affiliation: Dr. Lütfi Kirdar Kartal Education and Research Hospital, İstanbul, Turkey.
authors.forename: Ramazan
authors.initials: R
authors.lastname: Yıldız
authors.affiliation: Department of Medical Oncology, Erciyes University, Kayseri, Turkey.
authors.forename: Veli
authors.initials: V
authors.lastname: Berk
authors.affiliation: Department of Medical Oncology, Dokuz Eylül University, İzmir, Turkey.
authors.forename: İlkay T
authors.initials: İT
authors.lastname: Unek
authors.affiliation: Yıldırım Beyazıt Education and Research Hospital, Ankara, Turkey.
authors.forename: Dilsen
authors.initials: D
authors.lastname: Colak
authors.affiliation: Marmara University School of Medicine, Division of Medical Oncology, Istanbul, Turkey.
authors.forename: Faysal
authors.initials: F
authors.lastname: Dane
authors.affiliation: Secuk University, Meram Medical Faculty, Konya, Turkey.
authors.forename: Caglayan
authors.initials: C
authors.lastname: Geredeli
authors.affiliation: Department of Medical Oncology, Dicle University, Diyarbakır, Turkey.
authors.forename: Abdurrahman
authors.initials: A
authors.lastname: Isıkdogan
keywords: gemcitabine-refractory patients; pancreatic cancer; prognostic factors